Catalent (NYSE:CTLT) Sets New 52-Week High – Here’s Why

Catalent, Inc. (NYSE:CTLT)’s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $63.47 and last traded at $63.47, with a volume of 344071 shares changing hands. The stock had previously closed at $63.07.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on CTLT. Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. William Blair reissued a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Robert W. Baird reissued a “neutral” rating and set a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. Finally, StockNews.com lowered shares of Catalent from a “hold” rating to a “sell” rating in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating and seven have given a hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $63.40.

Catalent Price Performance

The firm has a market cap of $11.52 billion, a P/E ratio of -28.09, a P/E/G ratio of 2.70 and a beta of 1.15. The business’s fifty day moving average price is $60.36 and its two-hundred day moving average price is $59.11. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.10) EPS. As a group, equities research analysts anticipate that Catalent, Inc. will post 0.78 EPS for the current year.

Insider Activity

In related news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at $646,849.50. This trade represents a 20.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,114 shares of company stock worth $305,931. 0.31% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC grew its position in Catalent by 1.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company’s stock worth $619,000 after purchasing an additional 185 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd grew its position in Catalent by 1.1% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company’s stock worth $1,179,000 after purchasing an additional 220 shares during the last quarter. Crossmark Global Holdings Inc. grew its position in Catalent by 2.6% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company’s stock worth $553,000 after purchasing an additional 229 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its position in Catalent by 3.8% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company’s stock worth $432,000 after purchasing an additional 278 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in Catalent by 26.9% in the 3rd quarter. GAMMA Investing LLC now owns 1,310 shares of the company’s stock worth $79,000 after purchasing an additional 278 shares during the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.